A clinical-stage biotech firm developing proprietary medical robotics platforms for minimally invasive surgery with minimal current revenue but significant cash flow from financing activities.
Early-stage biotech investors may value the company for its proprietary medical robotics platform with potential for high returns upon successful clinical trials and commercialization. The strong cash flow from financing activities suggests management can secure necessary capital to extend operations beyond current cash reserves. If the technology achieves breakthrough status in minimally invasive surgery, market valuation could expand significantly upon product launch.
The company faces existential risk with no revenue stream and a cumulative loss history totaling over $35 million since 2022. Operating expenses have remained stubbornly high at $11.6 million annually without any path to profitability visible in current financials. Investors must consider the significant dilution risk as the company burns through its cash reserves while waiting for uncertain regulatory approvals.
Microbot Medical Inc. is a clinical-stage biotechnology company developing innovative medical robotics systems to advance minimally invasive surgery. While currently non-revenue generating, the company focuses on research and development within the advanced surgical equipment sector targeting global healthcare markets. The firm leverages its proprietary technology platform to create next-generation robotic solutions for surgeons worldwide.
The company reported a net loss of $11.4 million in 2024, consistent with previous years showing losses between $10.7M and $13.2M over the last three years. Cash flow from operations remains negative at $8.8 million while cash flow from financing provided $7.9 million, indicating heavy reliance on capital markets to fund operations. Total assets of $6.0 million are primarily comprised of cash equivalents and marketable securities rather than commercializable products or revenue-generating infrastructure.
The medical robotics industry is experiencing rapid growth driven by demand for minimally invasive surgical solutions and advanced healthcare technologies. Companies in this sector face high regulatory barriers and lengthy development cycles before achieving commercial revenue. Market leaders typically require substantial R&D investment and face intense competition from established surgical equipment manufacturers.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $13.3M | $9.9M | $11.6M |
| Operating Income | $-13.3M | $-9.9M | $-11.6M |
| R&D | $7.7M | $5.7M | $6.6M |
| G&A | $5.5M | $4.1M | $5.0M |
| Stock-Based Comp | $1.8M | $1.4M | $1.3M |
| D&A | $102.0K | $106.0K | $91.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-13.3M | $-9.9M | $-11.6M |
| Income Tax | $-113.0K | $885.0K | $-182.0K |
| Continuing Ops | $-13.2M | $-10.7M | $-11.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-13.2M | $-10.7M | $-11.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-13.2M | $-10.7M | $-11.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $8.8M | $7.9M | $5.8M |
| Cash & Equivalents | $2.4M | $2.5M | $3.1M |
| Marketable Securities | $5.8M | $3.9M | $2.4M |
| Prepaid Expenses | $532.0K | $152.0K | $300.0K |
| Other Current Assets | $80.0K | $1.4M | $49.0K |
| Long-Term Assets | $723.0K | $406.0K | $212.0K |
| PP&E (Net) | $221.0K | $146.0K | $80.0K |
| Operating Leases | $502.0K | $260.0K | $132.0K |
| Other LT Assets | $0 | $0 | $0 |
| Total Assets | $9.5M | $8.3M | $6.0M |
| Current Liabilities | $2.1M | $3.8M | $2.5M |
| Accounts Payable | $116.0K | — | — |
| Current Leases | $283.0K | $191.0K | $70.0K |
| Other Current Liab | $0 | $2.6M | $165.0K |
| Long-Term Liabilities | $179.0K | $40.0K | $41.0K |
| LT Operating Leases | $179.0K | $40.0K | $41.0K |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $2.2M | $3.8M | $2.5M |
| Shareholders' Equity | $7.3M | $4.5M | $3.5M |
| Retained Earnings | $-68.8M | $-79.5M | $-90.9M |
| Total L&E | $9.5M | $8.3M | $6.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-13.2M | $-10.7M | $-11.4M |
| Non-Cash Adjustments | $1.9M | $3.6M | $1.8M |
| Working Capital Changes | $-254.0K | $-1.4M | $804.0K |
| Cash from Operations | $-11.5M | $-8.5M | $-8.8M |
| Capital Expenditures | $84.0K | $33.0K | $25.0K |
| Cash from Investing | $-3.8M | $2.0M | $1.5M |
| Cash from Financing | $4.3M | $6.6M | $7.9M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-11.1M | $-2.0K | $646.0K |
| Beginning Cash | $13.6M | $2.5M | $2.5M |
| Ending Cash | $2.5M | $2.5M | $3.2M |
The company operates primarily as a research and development entity with no commercial revenue streams yet, directing capital toward product development and clinical trials. Its financial profile is defined by high operating expenses driven by general and administrative costs, R&D initiatives, and share-based compensation rather than traditional product sales segments.
Complete lack of revenue generation with a significant retained earnings deficit creating dependence on external capital markets. High burn rate with operating expenses exceeding $11 million against negligible cash flow from operations. Significant dilution risk as the company relies on equity financing to fund R&D and extend its cash runway. Regulatory approval uncertainties for new medical devices in the competitive surgical robotics industry.
Proprietary medical robotics technology platform designed for minimally invasive surgical applications. Strong strategic financing capability evidenced by substantial cash flow from financing activities relative to current asset base. Potential for high-margin commercialization once clinical trials are successful and products reach market.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.